Febrile status epilepticus and epileptogenesis: The FEBSTAT study

Darrell V Lewis1, Douglas R Nordli2, Douglas R Nordli2

  • 1Department of Pediatrics (Neurology), Duke University Medical Center, Durham, North Carolina, USA.

Epilepsia Open
|August 7, 2025
PubMed

Insights

Prolonged febrile seizures in infants can cause hippocampal injury, visible on MRI in 10% of cases. This injury significantly increases the risk of developing temporal lobe epilepsy years later.

Area of Science:

  • Pediatric Neurology
  • Neuroimaging
  • Epileptology

Background:

  • Febrile status epilepticus (FSE) is a prolonged seizure in infants triggered by fever.
  • The long-term neurological consequences of FSE, particularly hippocampal injury and subsequent epilepsy, require further elucidation.

Purpose of the Study:

  • To investigate the incidence and evolution of hippocampal injury following FSE.
  • To determine the association between acute FSE-related hippocampal injury and the development of epilepsy, specifically temporal lobe epilepsy.

Main Methods:

  • Prospective enrollment of over 200 infants experiencing FSE in the multicenter FEBSTAT study.
  • Serial magnetic resonance imaging (MRI) including initial scans within days of FSE and follow-ups at 1, 5, and 10 years.
  • Electroencephalography (EEG) to assess post-ictal abnormalities.
  • Hippocampal volume and apparent diffusion constant measurements.

Main Results:

  • Acute unilateral hyperintense hippocampal T2 signal on MRI was observed in 10% of infants post-FSE.
  • A significant association was found between focal EEG abnormalities and hippocampal T2 hyperintensity.
  • Follow-up MRIs revealed marked hippocampal volume loss by 1 year, evolving into hippocampal sclerosis in 70% of those with initial T2 hyperintensity.
  • Ten-year cumulative epilepsy incidence was 30% overall, but 71% in those with acute hippocampal T2 hyperintensity.
  • Medial temporal lobe epilepsy incidence was 39% in those with acute hippocampal T2 hyperintensity, versus 4% in the entire cohort.

Conclusions:

  • Acute hippocampal injury following FSE is identifiable via MRI and EEG.
  • This injury leads to significant hippocampal volume loss and sclerosis over time.
  • Infants with FSE-induced hippocampal injury have a substantially elevated risk of developing epilepsy, particularly temporal lobe epilepsy.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
280
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
593
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
450
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
650
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
278
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
516